

Antifungal Activity of Linear and Disulfide-Cyclized Ultrashort Cationic Lipopeptides Alone and in Combination with Fluconazole Against Vulvovaginal *Candida* spp.

Paulina Czechowicz (✉ paulina.czechowicz.umedwroc@gmail.com)

Wrocław Medical University

Damian Neubauer

Medical University of Gdańsk

Joanna Nowicka

Wrocław Medical University

Wojciech Kamysz

Medical University of Gdańsk

Grażyna Gościński

Wrocław Medical University

Research Article

Keywords: *Candida*, biofilm, vulvovaginal candidiasis, antifungal, lipopeptides, synergy, cationic lipopeptides, cyclic lipopeptides, disulfide cyclization

Posted Date: April 21st, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-440442/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Vulvovaginal candidiasis (VVC) occurs in over 75% of women at least once during their lifetime and is an infection that significantly affects their health. *Candida* strains resistant to standard azole antifungal therapy and relapses of VVC are more and more common. Hypothetically, biofilm is one of the main reasons of relapses and failure of the therapy. Ultrashort cationic lipopeptides (USCLs) exhibit high antimicrobial activities. Our previous study on USCLs revealed that disulfide cyclization can result in selective antifungal compounds. Therefore, four USCL were selected and their antifungal activity were studied on 62 clinical strains isolated from VVC. The results showed that cyclic analogs have increased selectivity between fungal cells and keratinocytes and improved anticandidal activity than their linear analogs against both planktonic and biofilm cultures. On the other hand, linear lipopeptides in combination with fluconazole showed the synergistic effect. It was found that the minimum inhibitory concentrations of the tested compounds in combination with fluconazole were at least four times lower than when used separately. Our results indicate that combination therapy of VVC with USCLs and fluconazole at low non-toxic concentrations can be beneficial owing to the synergistic effect. However, further *in vivo* studies are needed to confirm this hypothesis.

Introduction

Vulvovaginal candidiasis (VVC) is the second most common type of vaginal infection, significantly reducing the quality and comfort of women's lives. According to estimates, more than 75% of women in childbearing age worldwide will experience a symptomatic episode of VVC at least once during their lifetime. Undoubtedly, this infection is of significant importance for women's health and represents a major challenge that modern medicine should be able to deal with. Meanwhile, it is often underestimated, while conventional treatments often result in therapeutic failure and/or recurrence of the infection¹⁻⁶. Typical recurrent VVC (RVVC), defined as four or more episodes per year, affects at least 10% of patients. At the same time, *Candida* can colonize the vagina and about 1/5 of women are asymptomatic carriers^{1,2,4,5}. As the detailed pathomechanism of vaginal mucosa invasion by yeast-like fungi remains unclear, the prevention and treatment of the infection is significantly hampered^{2,3,7}. *Candida albicans* remains the most common etiological factor of VVC, but for many years an increasing percentage of NCAC (Non-*Candida albicans Candida*) fungi has been observed among vaginal isolates, such as *Candida glabrata*, *Candida parapsilosis* or *Candida lusitanae*^{5,8-10}. Many researchers are inclined to the hypothesis that the ability to form a highly resistant biofilm structure by these strains is one of the causes of therapy failure in VVC^{2,3,5,7,8,10,11}. At the same time, there is also an increase in the percentage of yeast-like fungi, especially among the NCAC group, resistant to the available antifungal drugs^{1,2,4,5}. Therefore, the great amount of effort that has been put into the research on new antifungal therapies, including those against biofilm, is not surprising.

One of the promising classes of compounds are lipopeptides¹²⁻¹⁵. In general, lipopeptides consist of a peptide fragment and conjugated lipid residue(s). Lipopeptides can be divided into subclasses, of which

ultrashort cationic lipopeptides (USCLs) are among the most effective against fungal strains. These compounds consist of a peptide with at most 7 amino acid residues with a net positive charge owing to the occurrence of basic amino acids such as arginine or lysine. The most common hydrophobic fragment of USCLs is a fatty acid chain. In effect, USCLs are amphiphilic and can easily interact with the negatively charged pathogen membrane. In the case of fungi, lipopeptides interact with negatively charged residues of sialic acid and phosphatidylinositol found in the cell membrane of these microorganisms^{16,17}. Their mode of action is based on the permeabilization of the membrane bilayers, what leads to cell death^{13-15,18}. They can exhibit plenty of biological properties, such as antibacterial, antifungal, antibiofilm, antiadhesive, anticancer and surface activities¹⁹. On the other hand, USCLs can be noticeably lytic to erythrocytes and cytotoxic to normal human cells^{13,15,18}. One of the well-studied USCL with a proven antimicrobial activity is C₁₆-KKKK-NH₂ (C₁₆ – palmitic acid) that contains four L-lysine (K – L-lysine) residues²⁰⁻²⁴. Our previous study on this lipopeptide and its analogs revealed that the substitution of L-lysine by L-arginine residue and disulfide-cyclization can result in compounds with improved antimicrobial activity and selectivity between *Candida* strains and human cells¹³. Based on our previous results, four lipopeptides with the most favorable antifungal properties were selected for further study – C₁₆-KKKK-NH₂, C₁₆-KRKK-NH₂, C₁₆-CKKKKC-NH₂, and C₁₆-CKRKKC-NH₂. The lipopeptides with cysteine residues were cyclized through intramolecular disulfide bridge formation¹³. Undoubtedly, compounds with different mode of action can potentiate each other's antifungal activity. It was found that a combination of some lipopeptides (e.g. surfactin) with common antifungal drugs (e.g. azoles) can result in a synergistic effect²⁵⁻³³.

In the context of fungal infections, interactions between conventionally used fluconazole and various AMPs are being investigated more and more frequently^{27,34-39}. The literature includes several studies on the impact of cationic ultrashort lipopeptides on fungi, including for example dermatophytes, but to the best of our knowledge none of these reports concerned isolates from VVC⁴⁰.

The aim of the study was to determine the antifungal activity of two linear lipopeptides: C₁₆-KKKK-NH₂ (**L1**), C₁₆-KRKK-NH₂ (**L2**) and their two cyclic analogs: C₁₆-CKKKKC-NH₂ (**C1**) and C₁₆-CKRKKC-NH₂ (**C2**) against 62 clinical strains of various species of *Candida* isolated from vulvovaginal candidiasis, both in planktonic and biofilm form. Moreover, studies on the potential synergistic or additive effects of combinations of fluconazole with these compounds have been carried out.

Results

Minimum inhibitory concentration

Fluconazole and four tested lipopeptides exhibited antimicrobial activity against planktonic cultures of all *Candida* strains.

The most common MIC of fluconazole was $\leq 0.125 \mu\text{g/mL}$ and was determined for 77% of the strains (48/62). All of them were *C. albicans* and only single strains of this species demonstrated a slightly higher MIC, not exceeding $2 \mu\text{g/mL}$. One isolate (*C. lusitanae*) was resistant to fluconazole (MIC = $64 \mu\text{g/mL}$). The remaining NCAC strains exhibited minimum inhibitory concentrations of tested azole of $4 \mu\text{g/mL}$ (all five *C. glabrata* isolates) or less. The distribution of MIC values of fluconazole is presented below in Fig. 1A.

Minimum inhibitory concentrations of lipopeptide **L1** were in the range $2\text{--}64 \mu\text{g/mL}$, with $32 \mu\text{g/mL}$ as the most common value (26/62, $\approx 42\%$). No significant differences among various *Candida* species were observed. The cyclic analog of this lipopeptide (**C1**) exhibited MIC distribution in the lower concentration range between 1 and $32 \mu\text{g/mL}$. For almost half (30/62, $\approx 48\%$) of the tested strains, MIC of **C1** was $4 \mu\text{g/mL}$ and for 26 isolates ($\approx 42\%$) it was twice as high— $8 \mu\text{g/mL}$. No deviations in MICs were observed between different *Candida* species. MIC distribution for L1 and C1 is presented below in Fig. 1B.

The second pair of lipopeptides, the one with arginine residue, exhibited less pronounced differences in MIC distribution. MIC concentration range for **L2** was $1\text{--}32 \mu\text{g/mL}$, while for **C2** it was $1\text{--}16 \mu\text{g/mL}$. For nearly 50% (29/62, $\approx 47\%$) of strains, minimum inhibitory concentrations of linear lipopeptides were $16 \mu\text{g/mL}$, followed by $32 \mu\text{g/mL}$ (20/62, $\approx 32\%$). The most frequent concentration of the cyclic compound was $4 \mu\text{g/mL}$ (32/62, $\approx 52\%$). As with the first pair of lipopeptides, no difference in MIC distribution was observed for individual *Candida* species. MIC distribution of **L2** and **C2** lipopeptides is displayed in Fig. 1C.

To evaluate lipopeptides selectivity, the results of our previous study on cytotoxicity against HaCaT cell line (immortalized human keratinocytes) were included¹³. Geometric mean (GM) MIC values were calculated. Selectivity indices (SI) were calculated as the ratio of IC_{50} to GM. The results are presented in Table 1.

Table 1
Geometric mean of MICs (GM_MIC), IC_{50} and selectivity indices (SI)
of four tested lipopeptides.

Lipopeptide	GM_MIC [$\mu\text{g/mL}$]	IC_{50} (Neubauer et al. 2020)	SI
L1	26.46	23.5 ± 1.3	0.89
C1	4.89	26.9 ± 1.9	5.50
L2	15.47	4.3 ± 0.9	0.28
C2	3.83	33.8 ± 3.1	8.83

Minimum biofilm eradication concentration

Fungistatic fluconazole failed to eradicate the biofilm of *Candida* strains. For almost all strains (58/62, ≈ 94%) MBEC values were extremely high (512 µg/mL) and for the remaining isolates eradication concentrations were even higher. The distribution of MBECs are presented below in Fig. 2A.

In contrast to fluconazole, all four lipopeptides have proved to be effective in biofilm eradication. In the case of the first pair of lipopeptides **L1** and **C1** (consisting of lysine residues only), similarly to MICs, the obtained MBECs were significantly lower for cyclic lipopeptide than for the linear analog. The most common MBEC value for **L1** was 256 µg/mL (25/62, ≈ 40%), followed by 128 µg/mL (16/62, ≈ 26%) and concentration above 256 µg/mL (17/62, ≈ 27%). On the other hand, for the vast majority of strains (41/62, ≈ 66%) minimum biofilm eradication concentrations of the second lipopeptide (**C2**) were 64 µg/mL. Again, no differences in MBECs were observed in term of species. The results of MBEC value determination are shown in Fig. 2B.

The MBECs of lipopeptides **L2** and **C2** were very similar to those described above. In the case of cyclic lipopeptide, MBEC value of 64 µg/mL was definitely dominant (47/62, ≈ 76%). For the linear parent molecule, the values were more distributed. The most common MBEC was 256 µg/mL (30/62, ≈ 48%) followed by 128 µg/mL (16/62, ≈ 26%) and > 256 µg/mL (12/62, ≈ 19%). No differences for *C. albicans* versus NCAC fungi were observed. The results are presented below in Fig. 2C.

Geometric means of MBECs were calculated. If MBEC was above 256 µg/mL then 512 µg/mL was taken into calculations as the next theoretical concentration in the serial dilution method, but 1024 µg/mL was used if MBEC of fluconazole was above 512 µg/mL. Importantly, although this mathematical operation includes resistant strains in the calculations, their precise effective concentrations are not known. The calculated GM_MBECs of linear lipopeptides were congruent. In the case of **L1** it was 236.73 µg/mL and 223.86 µg/mL for the **L2** lipopeptide. The calculated GM_MBECs of cyclic analogs were similar. GM_MBEC of lipopeptide with an arginine residue (**C2**) was 65.45 µg/mL and 56.59 µg/mL for **C1**.

Fractional inhibitory concentration index (FIC_i)

To initially assess the interaction of each fluconazole-lipopeptide combination, 24 of the tested strains were randomly selected of which 15 isolates were *C. albicans* and the remaining 9 were from the NCAC group. The interpretation of FIC indices was as follows: FIC_i ≤ 0.5 indicates synergy (SYN), > 0.5 to ≤ 1.0 - addition (ADD), > 1.0 to ≤ 2.0 means indifference (IND) and FIC_i > 2.0 means antagonism (ANT)⁴¹. The results are collected in Fig. 3.

Although no synergy was observed among the tested fluconazole-lipopeptide pairs against *Candida* strains, an additive effect was determined, especially in the case of *C. albicans* isolates. The distribution of the results on the histograms (Fig. 3) clearly indicates that the additive effect is more frequent for both linear lipopeptides combined with fluconazole: **L1** (15/24, ≈ 63%) and **L2** (11/24, ≈ 46%). For cyclic analogs combined with fluconazole, the dominant result was indifference: ≈ 71% (17/24) for **C1** and ≈ 58% (14/24) for **C2**. A simultaneous use of cyclic USCLs with fluconazole has an antagonistic or neutral effect against strains of the NCAC group, e.g. *C. glabrata* and *C. kefyr*, in contrast to their linear

counterparts. The FIC index determined for *C. albicans* isolates was in agreement with the overall results, with an additive effect obtained mostly for linear lipopeptides.

As preliminary research on the FIC index was carried out on a small number of strains, it was decided to conduct the rest of the study with a pair of linear and cyclic analogs in order to investigate the interactions of USCLs with different structures more precisely. Based on the obtained results, two lipopeptides were selected for further experiments: linear **L1** and its cyclic analog **C1**. Both USCLs showed more favorable effects (Fig. 3, additive effect) against *Candida* in combination with fluconazole than lipopeptides with arginine residue.

The FIC indices of combinations of fluconazole-**L1** and fluconazole-**C1** were determined against the remaining 40 isolates. The results (64 isolates, reference strains included) are shown in Figs. 4 and 5.

In the case of the linear lipopeptide, the results obtained for all 64 strains were consistent with those described for 24 isolates (Fig. 3). Altogether, an additive effect with fluconazole was dominant (54/64, \approx 84%). A similar result was observed for *C. albicans* strains (48/53, \approx 91%). Among NCAC fungi, additive effect was the most frequent as well (6/11, \approx 55%), but it is difficult to draw strict conclusions due to a relatively small pool of strains. At first, cyclic **C2** seemed to have an indifferent effect in combination with the tested azole but a study on 64 strains revealed that addition is the most common result (34/64, \approx 53%) in reference to all *Candida* species and also in the case of *C. albicans* species. Unfortunately, this pair of USCL-fluconazole had still a predominantly neutral effect against NCAC group (7/11, \approx 64%).

Interestingly, the FIC index itself is an arithmetic mean of 8 obtained individual FIC values. When searching for the most advantageous combination of fluconazole-lipopeptide concentrations, it is the single FIC values (and the corresponding concentrations) that should be taken into account and interpreted. For the vast majority of strains and both USCLs-azole pairs, a synergistic effect could be observed ($\text{FIC} \leq 0.5$). This applies in particular to the linear lipopeptide **L1**. An analysis of the most beneficial (the lowest possible) FIC values of fluconazole-**L1** showed that synergy between these two compounds is achieved against \approx 72% (46/64) of the strains. Consistent results were obtained for *C. albicans* isolates (synergistic effect against 40/53, \approx 75% of strains). Synergy was also the most common among NCAC fungi (6/11, \approx 55%). In the case of cyclic USCL, synergistic effect occurred less often when single FIC values were analyzed, with the additive effect being dominant. For the fluconazole-**C1** combination, synergism was present in \approx 23% (15/64) of cases, including in \approx 26% (14/53) concerned *C. albicans* and only \approx 10% (1/11) NCAC. At the same time, additive effect was achieved in \approx 61% (39/64) – \approx 62% for *C. albicans* and in \approx 55% (6/11) of the remaining strains. Lipopeptide concentrations corresponding to FIC values indicating synergy were at least 4 times lower than MICs obtained for these strains. For example, when MIC value of **L1** was 64 $\mu\text{g/mL}$, synergistic effect was observed when a combination of 8 $\mu\text{g/mL}$ of lipopeptide and 0.031 $\mu\text{g/mL}$ of fluconazole was used. The concentrations of the discussed fluconazole-**L1** pair corresponding to synergistic effect, compared to the obtained MIC values, are shown in Table 2. The corresponding data for the fluconazole-**C1** combination was included in the supplementary material.

Table 2
Concentrations of fluconazole-L1 combination exhibited a synergistic effect against 46 isolates of *Candida* strains.

FIC			
MIC of L1 [µg/mL]	L1 [µg/mL]	Fluconazole [µg/mL] (random order)	No. of strains against which this combination was effective
16	2	0.002 or 0.5	2 × <i>C. albicans</i> 1 × <i>C. glabrata</i>
16	4	0.002 or 0.031 or 0.5	5 × <i>C. albicans</i>
32	8	0.002 or 0.031	8 × <i>C. albicans</i>
32	4	0.002 or 0.004 or 0.5	6 × <i>C. albicans</i> 1 × <i>C. glabrata</i>
32	2	0.002 or 0.063 or 1	5 × <i>C. albicans</i> 3 × <i>C. glabrata</i>
64	16	0.002 or 0.016	3 × <i>C. albicans</i>
64	8	0.002 or 0.031	6 × <i>C. albicans</i>
64	4	0.002 or 0.004	4 × <i>C. albicans</i>
64	2	0.004 or 1	1 × <i>C. albicans</i> 1 × <i>C. lusitaniae</i>

Discussion

Being a local infection not associated with mortality, vulvovaginal candidiasis (VVC) is a clinical problem that is relatively often underestimated in comparison to other types of infections, including other candidosis. Meanwhile, it is a common disease affecting a vast majority of women in the world and having a negative impact on their quality of life and health^{9,42}. Because the pathomechanism of VVC is still not fully understood, the achievement of therapeutic success is often difficult. Additionally, as the condition has a high tendency to relapse, it is often a challenge for both the patient and the clinician⁴³. Previous studies on the development of vaginal mycosis indicate a multifactorial pathological mechanism, including the formation of biofilm by *Candida* strains and the growing resistance of yeast-like fungi to conventionally used antimycotics^{3,5,9,44}. Among the etiological factors of VVC, *C. albicans* remains the most common, although other species are also increasingly often isolated, such as *C.*

glabrata, *C. lusitaniae*, *C. parapsilosis*, or *C. kefyr*^{3,5,9}. Therefore, the search for new antimicrobial agents, including antifungal agents, also focuses on anti-biofilm activity.

AMPs (including lipopeptides) are among antimicrobial compounds that are of great interest for researchers, especially in recent years. These are compounds with a broad spectrum of activity and a different mechanism of action compared to traditional antibiotics, which makes it much more difficult for microorganisms to acquire resistance to them^{13–15,18}. The compounds used in this study were ultrashort cationic lipopeptides (USCLs). In general, USCLs consist of at most 7 amino acid residues with a fatty acid attached. Usually, USCLs are rich in arginine or lysine, which makes them cationic (net positive charge). Owing to this structure, USCLs interact with the membrane bilayers of various microorganisms, permeabilize them and cause cell death^{13–15,18}. Based on our previous study, compounds with the most potent antifungal and antibiofilm activities were selected. Two with linear structure, one modified by replacing one lysine residue (K) with an arginine residue (R) – C₁₆-K₄KKK-NH₂ (**L1**) and C₁₆-KRKK-NH₂ (**L2**), as well as two cyclic analogs – C₁₆-CKKKKC-NH₂ (**C1**) and C₁₆-CKRKKC-NH₂ (**C2**)¹³. In the present study, antifungal activity of these lipopeptides was tested against 62 clinical strains of various *Candida* species isolated from VVC, both in planktonic and biofilm form. Reference strains of *C. albicans* ATCC 90028 and *C. glabrata* ATCC 15126 were also included. Moreover, combinations of the USCLs with fluconazole were tested for their potential synergistic or additive effect. The literature indicates the possibility of a beneficial effect of combinations of fluconazole with various AMPs against e.g. yeast-like fungi, most likely due to the different mechanisms of action of these two groups of compounds^{27,34–39}. Meanwhile, to the best of our knowledge, no such experiments have been performed using ultrashort cationic lipopeptides against *Candida* isolated from VVC.

With one exception of a single *C. lusitaniae* isolate (MIC = 64 µg/mL), all tested strains were found to be susceptible to fluconazole—the most common MIC was 0.125 µg/mL or less (Fig. 1A). This is not an unusual situation; more surprising is the fact of so frequent clinical therapeutic failures with this mycostatic. Considering the multifactorial pathomechanism of vaginal invasion by yeast-like fungi, their ability to form highly resistant biofilm structure may be the major cause of the ineffectiveness of conventionally used azoles. Hence the focus of research on compounds with antibiofilm activity^{10,45–47}. All four analyzed ultrashort lipopeptides showed activity against *Candida* strains. In the case of cyclic analogs, the achieved concentrations inhibiting the growth of planktonic cells are 2–3 times lower than those of their linear counterparts. The most common MIC value obtained for both cyclic lipopeptides was 4 µg/mL; ≈48% of cases for **C1** and ≈ 52% for **C2**. Analogous concentrations for linear lipopeptides were 32 µg/mL (≈ 42%) and 16 µg/mL (≈ 47%), respectively. On the other hand, when comparing the activity of USCLs consisting of only lysine residues with lipopeptides with one arginine residue, the differences still seem to depend on the cyclic/linear structure of the compared compounds. In the case of cyclic analogs, the differences between MICs for **C1** and **C2** are virtually unnoticeable, which can be easily observed by comparing the histograms presented in Figs. 1B and 1C, which is consistent with previous studies on reference *Candida* strains¹³. Generally, the antimicrobial activity of linear **L2** exceeds that of lipopeptide consisting exclusively of lysine. The most common MIC was 16 µg/mL and only ≈ 32% of the

determined MICs exceeded this value, while in the case of **L1**, as much as $\approx 69\%$ of MICs were higher than $16 \mu\text{g/mL}$. This finding is consistent with those of our earlier study in which activity against different *Candida* reference strains was analyzed¹³. Similarly to our previous reports, disulfide-cyclized lipopeptides were substantially more active against both biofilm and planktonic cultures than the corresponding parent molecules. It was mentioned by Neubauer et al. that cyclic lipopeptides seem to be much more active against various species of yeast-like fungi. There is an unconfirmed hypothesis that disulfide cyclized USCLs are transported inside the fungal cell, causing degradation of the cell membrane and its interior and leading to cell death⁴⁸. Also, the potential advantage of linear analogs with the arginine residue, observed both by Neubauer and in this study, may support the first reports of the accumulation of protamine (salmon) rich in cationic arginine as necessary for anti-*Candida* activity⁴⁸. The determined SIs (Table 1) of cyclic lipopeptides (5.50 and 8.83) are much higher than those of their linear counterparts (0.28 and 0.89). Those results are in agreement with the literature. It has been shown that linear short cationic lipopeptides with hexadecanoic acid chain exhibited no selectivity between pathogens and normal human cells^{13,15,18,49}. It is worth mentioning that for similar USCL, consisting of only two lysine residues ($\text{C}_{16}\text{-KK-NH}_2$), antifungal activity was already demonstrated, e.g. against *Cryptococcus neoformans* and dermatophytes^{40,50}.

Similar conclusions are provided by the analysis of the obtained concentrations of biofilm eradication. While fluconazole failed to deal with *Candida* biofilm (Fig. 2A), all lipopeptides tested were capable of eradicating this structure (Figs. 2B and 2C). Again, cyclic analogs exhibited enhanced antibiofilm activity than linear parent molecules. While the most common MBEC value of both cyclic USCLs was $64 \mu\text{g/mL}$ (against $\approx 66\%$ of strains for **C1** and $\approx 76\%$ for **C2**), the MBEC distribution for both linear compounds was more variable, with a dominant value of $256 \mu\text{g/mL}$ (against $\approx 40\%$ and $\approx 48\%$ of strains, respectively). However, there are no substantial differences between the values of eradicating concentrations obtained for analogs composed only of lysine residues versus compounds enriched with an arginine residue; the histograms from the obtained distribution of values for both cyclic and linear lipopeptides are almost identical (Fig. 1B and 1C). The calculated GM_MBECs support this thesis. The results of research on biofilm are also consistent with our previous reports¹³. Higher minimum concentrations of compounds obtained for the biofilm structure compared to planktonic cells are not surprising. Biofilms, both bacterial and fungal, are characterized by a much higher resistance to antimicrobial agents than planktonic cells. Moreover, biofilm is associated with therapeutic failure. A single strain can be characterized as susceptible or resistant to fluconazole if examined against planktonic cells or biofilm, respectively^{8,47}.

The present results showed that USCLs in combination with fluconazole can give various effects. The FIC indices obtained in the checkerboard method indicate that additive antifungal effect was obtained more frequently for a combination of fluconazole and linear lipopeptides than for cyclic ones. Preliminary experiments on 24 random *Candida* strains and combinations of all four USCLs with the tested azole showed that indifferent antifungal effect against vaginally isolated fungi was predominantly observed with cyclic USCLs ($\approx 71\%$ for **C1** and $\approx 58\%$ for **C2**). In the case of the **L2** lipopeptide, the additive effect

with fluconazole occurred more often than for its cyclic analog ($\approx 46\%$ vs $\approx 17\%$). Moreover, additive effect was the most frequent with **L1** ($\approx 63\%$). Analyzing the above data with regard to the *Candida* species (15 isolates of *C. albicans* vs 9 NCAC), the obtained results for cyclic lipopeptides are very similar - both *C. albicans* and other species represented an indifferent effect, while for strains from the NCAC group no additive effect was observed. A comparison of the effect of linear USCLs against *C. albicans* indicates the advantage of the analog consisting of four lysine residues, for which a vast majority has an additive effect (73%). Studies on the linear compound enriched with arginine and combined with fluconazole revealed that it had an additive and indifferent effect on a similar percentage of strains (53% and 47%, respectively). Due to the small number of isolates from the NCAC group, a detailed analysis of the distribution of the obtained results seems unreliable.

Lipopeptide **L1** was selected for further studies with fluconazole owing to promising results in the preliminary results discussed above. The cyclic analog was included in this study to learn how different structures of USCLs in combination with fluconazole can affect antifungal activity against strains derived from VVC. Although in the case of both tested cyclic compounds the indifference was definitely the dominant effect, in the case of **C1**, a negative (antagonistic) effect was observed less frequently than for **C2** (8% and 25%, respectively). Hence, testing of the remaining pool of 40 strains was performed on a pair of USCLs composed only of lysine residues. The overall FIC index analysis for the entire pool of 62 isolates and 2 reference strains confirmed the predominant additive effect of the fluconazole-**L1** combination: 84% in total, 91% including *C. albicans* strains and 55% of NCAC, although in this case, the relatively small number of isolates (11) should still be kept in mind. Interestingly, similar results were obtained for the cyclic lipopeptide, for which an additive effect was observed in 53% of cases, of which 60% against *C. albicans*. In the NCAC group, indifference remained the most frequent result (64%). The literature has described the possibility of a favorable antifungal effect due to combinations of fluconazole with various AMPs³⁴⁻³⁹. The use of compounds with different mechanisms of action is generally recommended. Combined antifungal therapy has many potential benefits, such as enhancement of the fungicidal effect and broadening the spectrum of activity, which enable to fight polymicrobial infections, reduce the dose of the compounds, and thus also reduce dose-dependent toxicity as well as overcome the resistance of microorganisms^{51,52}. It is noted that antimicrobial peptides interacting with the membrane bilayers could, in a way, sensitize *Candida* cells to fluconazole by increasing azole penetration into the cell, where its molecular target – 14 α -lanosterol demethylase (Erg enzyme)—is located, involved in ergosterol synthesis. In effect, the composition of the cell membrane changes; it liquefies and increases the permeability for K⁺ and ATP causing a fungistatic effect⁵³. On the other hand, the interaction of fluconazole with the cell membrane may enhance its permeabilization by various AMPs, including lipopeptides, and enhance their fungicidal activity^{51,54,55}. Other mechanisms that may be responsible for the synergistic effect of combining triazoles with compounds with a different mechanism of action include sequential inhibition of different stages in the mutual biochemical pathway or simultaneous interaction with the *Candida* cell wall and/or membrane⁵¹. However, this hypothesis remains unconfirmed as of today.

Last but not least, there is one more interesting aspect of research using the checkerboard method. Knowing the general nature of the interaction of the combination of fluconazole with the lipopeptide against *Candida*, the next step is to select the most favorable and effective concentrations of both compounds to combat fungi. For this purpose, the individual FIC (as the FIC index is the arithmetic mean of 8 different FIC values) obtained for a given pair of compounds should be interpreted and the corresponding concentrations selected. In this way, the most favorable (the lowest) FIC for each of the isolates was analyzed in both fluconazole-L1 and fluconazole-C1 combinations. In 72% of strains (75% of *C. albicans*, and 55% of NCAC) there was such a combination of the concentrations of linear lipopeptide and FLC for which FIC indicated a synergistic effect ($FIC \leq 0.5$). The most beneficial FICs for the cyclic lipopeptide still showed a predominant additive effect (61%), although a synergistic effect was also observed (23%). A detailed analysis revealed that the concentration of L1 in combination with fluconazole that result in synergy is up to four-fold lower (2 vs. 16 $\mu\text{g}/\text{mL}$) than when lipopeptide is used separately (MIC value, Table 2). The literature contains an increasing body of reports about the results of similar studies of interactions of different compounds, not always having any activity against *Candida* alone, indicating a synergistic effect of their combinations with a number of antimycotics, including triazoles. There is a great interest in research on amphiphilic Lactoferrin (LF and its derivatives – cationic peptides), the use of which together with fluconazole (and not only) results in a significant increase in fungistatic activity and a decrease in MIC values^{56–59}. Although the mechanisms responsible for this phenomenon remain unexplained, attention is drawn to the beneficial effects of cationic compounds, such as LF, which may enhance the hydrophobicity of the surface of microbial cells and potentiate the antifungal activity of other compounds⁵⁷. Another example is the advantageous synergistic effect of combinations with fluconazole of such positively charged compounds as microbicidal cationic oligomers, styrylpyridinium compounds, novel antimicrobial peptides such as KABT-AMP derivatives or ToAP2^{51,55,60,61}. Recently, the synergism of fluconazole with surfactin (SU) against *C. albicans* has been described in more detail. Suchodolski et al. showed that SU binds to chitin and β -glucan on the surface of fungal cells, exposing it to the components of the host's immune system. However, to achieve the necessary effect, there seems to be required a reduction or complete lack of ergosterol, resulting in the corresponding changes in cell membrane and this is ensured by the presence of fluconazole²⁷. Derivatives of quaternary ammonium compounds (QAC) are other compounds whose activity is similar to that of cationic surfactants and which at the same time have a structure similar to lipopeptides (positive charge, presence of a lipid chain). One representative of this group, compound K21, has recently been tested for antifungal activity for the first time. It seems to be an effective alternative to fluconazole against *Candida* strains resistant to this mycostatic. K21 also shows synergism with triazoles towards NCAC, including *C. dubliniensis* and *C. tropicalis*, but no such effect was observed for *C. albicans*⁶². Meanwhile, a combination of another quaternary ammonium compound, domiphen bromide, with miconazole (imidazole) showed a synergistic effect against not only *Candida* planktonic cells, but also a biofilm – although this effect did not occur in the case of triazoles, including fluconazole⁶³. On the other hand, the mechanism of action of benzimidazolium-based QAC gemini surfactants was identified as influence on ergosterol synthesis in a manner similar to that of triazoles. Nevertheless, benzimidazolium-

based QACs were more effective and their combination with fluconazole results in synergistic effect against various *Candida* species⁶⁴. There are also reports in the literature about the synergistic effect of USCL with a structure similar to **L1** and **L2** with fluconazole and other triazoles, as well as with amphotericin B or terbinafine against *Cryptococcus neoformans* fungi and various representatives of dermatophytes^{40,50}. However, the mechanism of interaction of the above-mentioned compounds alone and in combination against fungi remains unclear. The literature and our results together clearly demonstrate the enormous potential of ultrashort cationic lipopeptides as compounds enhancing the activity of the existing antimycotics.

Therefore, the results achieved in this work constitute another important premise in the search for antifungal compounds and their combinations with conventional mycobiotics. Moreover, our findings can contribute to the broadening of knowledge in the search for mechanisms involved in the interactions of various cationic compounds with target cells and other antimicrobial compounds. Importantly, the most serious problems to be solved before the actual use of USCLs in the treatment of fungal infections are their relatively high toxicity and unsatisfactory selectivity between microorganisms and human cells^{15,18}. The use of combination therapy has a potential to significantly reduce the concentration of lipopeptides effective against *Candida* and to reduce toxicity towards human cells.

Conclusions

The results of this study performed with clinical isolates of *Candida* confirmed high antifungal potency of USCLs which have previously been studied only with reference yeast strains. Among the four tested lipopeptides, the cyclic compounds **C1** and **C2** (C₁₆-CKKKKC-NH₂ and C₁₆-CKRKKC-NH₂) showed higher activity against planktonic cells and biofilm of *Candida* isolated from VVC than their linear analogs, **L1** and **L2** (C₁₆-KKKK-NH₂ and C₁₆-KRKK-NH₂). Both cyclic counterparts were also more selective to pathogens over human cells, as demonstrated by SIs. Although the linear lipopeptide with a single arginine residue appeared to be more active against planktonic cells than the USCL consisting of only four lysine residues, no similar relationship was observed for biofilm eradicating concentrations. With regard to VVC, it would be undoubtedly worthwhile to conduct studies on the toxicity of these compounds towards vaginal epithelium cell lines and to take into account a larger number of strains from the NCAC group. The study on the interactions of fluconazole combined with lipopeptides showed the advantage of linear USCLs over cyclic ones, especially C₁₆-KKKK-NH₂. The concentrations of the linear lipopeptides causing a synergistic effect against *Candida* turned out to be at least four-fold lower than when lipopeptides were used separately. Presumably, it would be possible to use a combination therapy, achieving beneficial fungicidal effects owing to the use of compounds with different mechanisms of action, against which the development of resistance would be significantly impeded, at low non-toxic and therefore safer concentrations.

Materials And Methods

Lipopeptides Synthesis

The compounds were obtained by using the method reported previously¹³. Lipopeptides were synthesized manually by solid-phase Fmoc/tBu methodology. Polystyrene resin modified by Rink Amide linker was used as the solid support (loading ca. 1.0 mmol/g; Orpegen Peptide Chemicals GmbH, Heidelberg, Germany). Deprotection of the Fmoc group was performed with a 20% (v/v) piperidine (Iris Biotech GmbH, Marktredwitz, Germany) solution in DMF (*N,N*-dimethylformamide; POCH, Avantor, Gliwice, Poland) for 15 min. Acylation was conducted with a mixture of DIC:OxymaPure:Fmoc-AA-OH (mole ratio 1:1:1; DIC – *N,N*-diisopropylcarbodiimide) dissolved in DMF:DCM (1:1, v/v; DCM – dichloromethane, Chempur, Piekary Slaskie, Poland) in fourfold excess based on the resin for 1.5 h (DIC and OxymaPure; Iris Biotech GmbH, Marktredwitz, Germany). Fmoc-L-Arg(Pbf)-OH, Fmoc-L-Lys(Boc)-OH, Fmoc-L-Cys(Trt)-OH (amino acids were purchased from Orpegen Peptide Chemicals GmbH Heidelberg, Germany), and hexadecanoic acid (C16, palmitic acid; Merck, Darmstadt, Germany) were used in coupling reactions. After deprotection and coupling reactions, the resin was rinsed with DMF and DCM and subsequently the chloranil test was carried out. The peptides were cleaved from the resin using one of the mixtures; (A) TFA (trifluoroacetic acid; Apollo Scientific, Denton, UK), EDT (1,2-ethanedithiol; Merck, Darmstadt, Germany), TIS (triisopropylsilane; Iris Biotech GmbH, Marktredwitz, Germany), and deionized water (92.5:2.5:2.5:2.5, v/v/v/v); (B) TFA, TIS, and deionized water (95:2.5:2.5, v/v/v). Mixture A was used with peptides containing a cysteine residue, whereas mixture B was used for the remaining peptides. Cleavage was accomplished within 1.5 h under stirring. Then the peptides were precipitated with cooled diethyl ether (POCH, Avantor, Gliwice, Poland) and lyophilized. The crude peptide with cysteine was dissolved in 20% (v/v) acetic acid (Chempur, Piekary Slaskie, Poland) solution (0.5 g/L) and oxidized with iodine to obtain the peptide with intramolecular disulfide bridge. The peptides were purified by RP-HPLC. Pure fractions (>95%, HPLC) were collected and lyophilized. The identity of all compounds was confirmed by mass spectrometry (ESI-MS). The sequences of the synthesized lipopeptides were as follows: linear C₁₆-K₄-NH₂ (**L1**) and C₁₆-K₃-NH₂ (**L2**), cyclic: C₁₆-C₄-NH₂ (**C1**) and C₁₆-C₃-NH₂ (**C2**).

Candida Strains

Microbiological assays were performed on 62 clinical isolates of various *Candida* species. The vast majority of strains were identified as *C. albicans* (52), while the remaining strains belonged to the NCAC group: i.e. *C. glabrata* (5), *C. lusitanae* (2), *C. kefyr* (2), and *C. parapsilosis* (1). All strains were originally isolated from the vaginas of women with vulvovaginal candidiasis and were deposited in the Internal Collection of the Department of Microbiology, Wrocław Medical University. Two reference strains of *C. albicans* ATCC 90028 and *C. glabrata* ATCC 15126 (PCM, Polish Academy of Sciences, Wrocław) were included in all experiments.

The study protocol was approved by the local Bioethics Committee of Wrocław Medical University (No. 774/2018, approval date: December 27, 2018). All experiments were performed in accordance with relevant guidelines and regulations.

Minimum inhibitory concentration

The first part of the study aimed to determine minimum inhibitory concentrations (MICs) of fluconazole and four lipopeptides against *Candida* strains. The research was carried out in accordance with Clinical and Laboratory Standards Institute guidelines⁶⁵. Suspensions of *Candida* strains (subcultured for 24 hours on Sabouraud Dextrose Agar with chloramphenicol at a concentration of 100 mg/L) in sterile 0.9% NaCl were diluted in RPMI 1640 (Merck, KGaA, Darmstadt, Germany) to a final concentration of $1-5 \times 10^3$ CFU per mL. The test compounds dissolved in DMSO (Merck, KGaA, Darmstadt, Germany) for fluconazole and in sterile distilled water for lipopeptides were diluted in RPMI 1640 on 96-well polystyrene plates to a final range of concentrations 0.125–128 µg/mL (fluconazole) and 0.5–256 µg/mL (USCLs). After the addition of inoculums, all plates were incubated for 24 hours at 37 °C. In the case of fungistatic fluconazole the MIC value is defined as the concentration which inhibits at least 50% of fungal growth. In order to determine the most accurate MIC end-point value, cell densities were determined spectrophotometrically at 530 nm (BiochromAsys UVM 340 Microplate Spectrophotometer, Biochrom Ltd, USA). To calculate the MIC value, the following equation was used: $(OD_{\text{well}} - OD_{\text{background}}) / (OD_{\text{growth_control}} - OD_{\text{background}}) \times 100\%$. Minimum inhibitory concentrations of lipopeptides were the lowest concentrations at which inhibition of fungal growth was noticeable. All experiments were conducted in triplicate and included growth and a sterility control.

Minimum biofilm eradication concentration

The determination of minimum biofilm eradication concentrations (MBECs) of all five compounds was performed on 96-well polystyrene flat-bottom plates. 24-hour cultures of *Candida* were diluted with RPMI 1640 to obtain a final concentration of $1-5 \times 10^6$ cells per mL and 100 µL of cell suspension was added into each well of the test plate. The plates were incubated for 24 h at 37 °C in order to produce a mature biofilm. After incubation the biofilms were rinsed three times with sterile 0.9% NaCl. Subsequently, fluconazole was added with a final range of concentrations of 1–512 µg/mL, while the lipopeptides concentration ranged between 0.5 and 256 µg/mL. The plates were again incubated overnight at 37 °C. Visualization of results was carried out with a MTT solution (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide), Merck, KGaA, Darmstadt, Germany) which is reduced by metabolically active sessile cells of biofilm to purple/navy blue formazan compounds⁶⁶. Yellow MTT solution was added to each well of the plates and incubated for 3 hours in the dark at 37 °C. MBECs were the lowest concentrations of the compounds at which no color change was observed (no metabolically active yeast cells were present) as compared to the positive and negative controls. All experiments were conducted in triplicate.

Fractional inhibitory concentration index

The checkerboard method was used to determine fractional inhibitory concentration index (FIC_i)⁶⁷. Each lipopeptide was prepared on a 96-well polystyrene plate with concentrations decreasing horizontally (1 to 8) while the concentrations of fluconazole were decreasing vertically (A to H). The highest lipopeptide

and fluconazole concentrations were set at 2×MIC individually for each strain. Then the lipopeptides and fluconazole were serially diluted. In each well of the plates prepared as above, different lipopeptide-fluconazole concentrations were obtained. Inoculum of *Candida* strains were prepared as described for the determination of MIC (final concentration of $1-5 \times 10^3$ CFU per mL in RPMI 1640). After the yeast suspension was added, the plates were incubated for 24 hours at 37 °C. Inhibition of *Candida* growth was assessed visually. To calculate the FIC index, the following formula was used:

See formula in the supplementary files.

MIC values of compound A (lipopeptide) and B (fluconazole) were obtained in the first part of the research. A and B values were concentrations of the compounds determined using the checkerboard method. The sum of the ratios of these values (FIC_A, FIC_B) was FIC and after it was divided by n (number of FICs), the FIC index was obtained. Interpretation of the results was consistent with EUCAST guidelines⁴¹ as follows: $FIC_i \leq 0.5$ indicates synergy (SYN), >0.5 to ≤ 1.0 - addition (ADD), >1.0 to ≤ 2.0 indifference (IND) and $FIC_i > 2.0$ means antagonism (ANT).

Declarations

Acknowledgements

This research was financially supported by the Ministry of Health subvention according to number of STM.A130.20.102 from the IT Simple system of Wroclaw Medical University.

Author contributions

P.C, J.N. and G.G. designed this study. P.C. performed the experiments. P.C. and J.N. analyzed the results. P.C. and D.N. wrote the manuscript and prepared the figures. W.K. and G.G. revised the manuscript. All authors read and approved the final version of this manuscript.

Additional information

Competing Interests Statement

The authors declare that they have no competing interests.

Data Availability Statement

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

1. Sobel, J. D. Vulvovaginal candidosis. *Lancet* **369**, 1961–1971 (2007).

2. Gonçalves, B. *et al.* Vulvovaginal candidiasis: epidemiology, microbiology and risk factors. *Crit. Rev. Microbiol.***42**, 905–927 (2016).
3. Muzny, C. A. & Schwebke, J. R. Biofilms: an underappreciated mechanism of treatment failure and recurrence in vaginal infections. *Clin. Infect. Dis.***61**, 601–606 (2015).
4. Brandolt, T. M. *et al.* Prevalence of *Candida* spp. in cervical-vaginal samples and the in vitro susceptibility of isolates. *Brazilian J. Microbiol.***48**, 145–150 (2017).
5. Hacioglu, M., Guzel, C. B., Savage, P. B. & Seher Birteksoz Tan, A. Antifungal susceptibilities, in vitro production of virulence factors and activities of ceragenins against *Candida* spp. Isolated from vulvovaginal candidiasis. *Med. Mycol.***57**, 291–299 (2019).
6. Sherry, L. *et al.* Biofilms formed by isolates from recurrent vulvovaginal candidiasis patients are heterogeneous and insensitive to fluconazole. *Antimicrob. Agents Chemother.***61**, 1–4 (2017).
7. Swidsinski, A. *et al.* Vulvovaginal candidiasis: histologic lesions are primarily polymicrobial and invasive and do not contain biofilms. *Am. J. Obstet. Gynecol.***220**, 91.e1-91.e8 (2019).
8. Harriott, M. M., Lilly, E. A., Rodriguez, T. E., Fidel, P. L. & Noverr, M. C. *Candida albicans* forms biofilms on the vaginal mucosa. *Microbiology***156**, 3635–3644 (2010).
9. Paiva, L. C. F., Vidigal, P. G., Donatti, L., Svidzinski, T. I. E. & Consolaro, M. E. L. Assessment of in vitro biofilm formation by *Candida* species isolates from vulvovaginal candidiasis and ultrastructural characteristics. *Micron***43**, 497–502 (2012).
10. Rodríguez-Cerdeira, C. *et al.* Biofilms and vulvovaginal candidiasis. *Colloids Surfaces B Biointerfaces***174**, 110–125 (2019).
11. Harriott, M. M. & Noverr, M. C. Importance of *Candida*-bacterial polymicrobial biofilms in disease. *Trends Microbiol.***19**, 557–563 (2011).
12. Dawgul, M., Barańska-Rybak, W., Bielińska, S., Nowicki, R. & Kamysz, W. Wpływ peptydów przeciwdrobnoustrojowych na biofilm *Candida*. *Alerg. Astma Immunol.***15**, 220–225 (2010).
13. Neubauer, D. *et al.* Effect of disulfide cyclization of ultrashort cationic lipopeptides on antimicrobial activity and cytotoxicity. *Int. J. Mol. Sci.***21**, 1–30 (2020).
14. Czechowicz, P. & Nowicka, J. Antimicrobial activity of lipopeptides. *Postep. Mikrobiol.***57**, 213–227 (2018).
15. Mangoni, M. L. & Shai, Y. Short native antimicrobial peptides and engineered ultrashort lipopeptides: Similarities and differences in cell specificities and modes of action. *Cell. Mol. Life Sci.***68**, 2267–2280 (2011).
16. Jones, L., Hobden, C. & O’Shea, P. Use of a real-time fluorescent probe to study the electrostatic properties of the cell surface of *Candida albicans*. *Mycol. Res.***99**, 969–976 (1995).
17. Lohan, S., Cameotra, S. S. & Bisht, G. S. *Systematic study of non-natural short cationic lipopeptides as novel broad-spectrum antimicrobial agents. Chemical Biology and Drug Design* vol. 82 (2013).
18. Makovitzki, A., Avrahami, D. & Shai, Y. Ultrashort antibacterial and antifungal lipopeptides. *Proc. Natl. Acad. Sci. U. S. A.***103**, 15997–16002 (2006).

19. Greber, K. E. Synthesis and Surface Activity of Cationic Amino Acid-Based Surfactants in Aqueous Solution. *J. Surfactants Deterg.***20**, 1189–1196 (2017).
20. Serrano, G. N., Zhanel, G. G. & Schweizer, F. Antibacterial activity of ultrashort cationic lipo- β -peptides. *Antimicrob. Agents Chemother.***53**, 2215–2217 (2009).
21. Hensel, B. *et al.* Low temperature preservation of porcine semen: influence of short antimicrobial lipopeptides on sperm quality and bacterial load. *Sci. Rep.***10**, 1–12 (2020).
22. Ciandrini, E. *et al.* Antimicrobial Activity of Different Antimicrobial Peptides (AMPs) Against Clinical Methicillin-resistant *Staphylococcus aureus* (MRSA). *Curr. Top. Med. Chem.***18**, 2116–2126 (2018).
23. Greber, K. E., Dawgul, M., Kamysz, W. & Sawicki, W. Cationic net charge and counter ion type as antimicrobial activity determinant factors of short lipopeptides. *Front. Microbiol.***8**, 1–10 (2017).
24. Sikorska, E. *et al.* Self-assembly and interactions of short antimicrobial cationic lipopeptides with membrane lipids: ITC, FTIR and molecular dynamics studies. *Biochim. Biophys. Acta - Biomembr.***1838**, 2625–2634 (2014).
25. Desmyttere, H. *et al.* Antifungal activities of bacillus subtilis lipopeptides to two venturia inaequalis strains possessing different tebuconazole sensitivity. *Front. Microbiol.***10**, 1–10 (2019).
26. Ceresa, C., Rinaldi, M. & Fracchia, L. Synergistic activity of antifungal drugs and lipopeptide AC7 against *Candida albicans* biofilm on silicone. *AIMS Bioeng.***4**, 318–334 (2017).
27. Suchodolski, J. *et al.* Fluconazole and lipopeptide surfactin interplay during *Candida albicans* plasma membrane and cell wall remodeling increases fungal immune system exposure. *Pharmaceutics***12**, (2020).
28. Liu, X. *et al.* Optimization for the production of surfactin with a new synergistic antifungal activity. *PLoS One***7**, 1–9 (2012).
29. Maget-Dana, R., Thimon, L., Peypoux, F. & Ptak, M. Surfactin/iturin A interactions may explain the synergistic effect of surfactin on the biological properties of iturin A. *Biochimie***74**, 1047–1051 (1992).
30. Tabbene, O. *et al.* Synergistic fungicidal activity of the lipopeptide bacillomycin D with amphotericin B against pathogenic *Candida* species. *FEMS Yeast Res.***15**, fov022 (2015).
31. Ramachandran, R. *et al.* Evaluation of antifungal efficacy of three new cyclic lipopeptides of the class bacillomycin from *Bacillus subtilis* RLID 12.1. *Antimicrob. Agents Chemother.***62**, 1–11 (2018).
32. Kai, H. *et al.* Synergistic antifungal activity of KB425796-C in combination with micafungin against *Aspergillus fumigatus* and its efficacy in murine infection models. *J. Antibiot. (Tokyo)***66**, 479–484 (2013).
33. Dimkić, I. *et al.* Additive and synergistic effects of *Bacillus* spp. isolates and essential oils on the control of phytopathogenic and saprophytic fungi from medicinal plants and marigold seeds. *Biol. Control***87**, 6–13 (2015).
34. Sun, W., Zhang, L., Lu, X., Feng, L. & Sun, S. The synergistic antifungal effects of sodium phenylbutyrate combined with azoles against *Candida albicans* via the regulation of the Ras-cAMP-

- PKA signalling pathway and virulence. *Can. J. Microbiol. Can.***65**, 105–115 (2019).
35. Taveira, G. B. *et al.* Thionin-like peptide from *Capsicum annuum* fruits: Mechanism of action and synergism with fluconazole against *Candida* species. *BMC Microbiol.***16**, 1–13 (2016).
 36. de Aguiar, F. L. L. *et al.* The antiproliferative peptide Ctn[15-34] is active against multidrug-resistant yeasts *Candida albicans* and *Cryptococcus neoformans*. *Journal of Applied Microbiology* vol. 128 (2020).
 37. Maurya, I. K. *et al.* Mechanism of action of novel synthetic dodecapeptides against *Candida albicans*. *Biochim. Biophys. Acta - Gen. Subj.***1830**, 5193–5203 (2013).
 38. Mora-Navarro, C., Caraballo-León, J., Torres-Lugo, M. & Ortiz-Bermúdez, P. Synthetic antimicrobial β -peptide in dual-treatment with fluconazole or ketoconazole enhances the in vitro inhibition of planktonic and biofilm *Candida albicans*. *J. Pept. Sci.***21**, 853–861 (2015).
 39. Maurya, I. K. *et al.* Antifungal activity of novel synthetic peptides by accumulation of reactive oxygen species (ROS) and disruption of cell wall against *Candida albicans*. *Peptides***32**, 1732–1740 (2011).
 40. Simonetti, O. *et al.* In vitro activity of the lipopeptide derivative (Pal-lys-lys-NH₂), alone and in combination with antifungal agents, against clinical isolates of dermatophytes. *Br. J. Dermatol.***161**, 249–252 (2009).
 41. Diseases, I. Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents. *Clin. Microbiol. Infect.***6**, 503–508 (2000).
 42. Sherry, L. *et al.* Biofilms formed by isolates from patients are heterogeneous and insensitive to fluconazole. *Antimicrob Agents Chemother***61**, 1–4 (2017).
 43. Swidsinski, A. *et al.* Vulvovaginal candidiasis: histologic lesions are primarily polymicrobial and invasive and do not contain biofilms. *Am. J. Obstet. Gynecol.***220**, 91.e1-91.e8 (2019).
 44. Tulasidas, S., Rao, P., Bhat, S. & Manipura, R. A study on biofilm production and antifungal drug resistance among *Candida* species from vulvovaginal and bloodstream infections. *Infect. Drug Resist.***11**, 2443–2448 (2018).
 45. Capoci, I. R. G. *et al.* Propolis is an efficient fungicide and inhibitor of biofilm production by vaginal *Candida albicans*. *Evidence-based Complement. Altern. Med.***2015**, (2015).
 46. Consolaro, M. E. L., Albertoni, T. A., Svidzinski, A. E., Peralta, R. M. & Svidzinski, T. I. E. Vulvovaginal candidiasis is associated with the production of germ tubes by *Candida albicans*. *Mycopathologia***159**, 501–507 (2005).
 47. Scarsini, M. *et al.* Antifungal activity of cathelicidin peptides against planktonic and biofilm cultures of *Candida* species isolated from vaginal infections. *Peptides***71**, 211–221 (2015).
 48. Nagao, J. *et al.* Antifungal activity in vitro and in vivo of a salmon protamine peptide and its derived cyclic peptide against *Candida albicans*. *FEMS Yeast Res.***17**, fow099 (2016).
 49. Dawgul, M. A. *et al.* In vitro evaluation of cytotoxicity and permeation study on lysine- and arginine-based lipopeptides with proven antimicrobial activity. *Molecules***22**, 3–9 (2017).

50. Barchiesi, F. *et al.* In vitro activity of the synthetic lipopeptide PAL-Lys-Lys-NH₂ alone and in combination with antifungal agents against clinical isolates of *Cryptococcus neoformans*. *Peptides***28**, 1509–1513 (2007).
51. Yuan, Y., Zhou, F., Su, H. & Zhang, Y. Structural design of microbicidal cationic oligomers and their synergistic interaction with azoles against *Candida albicans*. *Sci. Rep.***9**, 1–11 (2019).
52. Bozkurt-Guzel, C., Hacıoglu, M. & Savage, P. B. Investigation of the in vitro antifungal and antibiofilm activities of ceragenins CSA-8, CSA-13, CSA-44, CSA-131, and CSA-138 against *Candida* species. *Diagn. Microbiol. Infect. Dis.***91**, 324–330 (2018).
53. Venisse, N., Grégoire, N., Marliat, M. & Couet, W. Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against *Candida albicans*. *Antimicrob. Agents Chemother.***52**, 937–943 (2008).
54. Czechowicz, P., Jaśkiewicz, M., Neubauer, D., Gościniak, G. & Kamysz, W. Anticandidal Activity of Omiganan and Its Retro Analog Alone and in Combination with Fluconazole. *Probiotics Antimicrob. Proteins* (2021) doi:10.1007/s12602-021-09757-9.
55. do Nascimento Dias, J. *et al.* Mechanisms of action of antimicrobial peptides ToAP2 and NDBP-5.7 against *Candida albicans* planktonic and biofilm cells. *Sci. Rep.***10**, 1–14 (2020).
56. Fernandes, K. E. & Carter, D. A. The antifungal activity of lactoferrin and its derived peptides: Mechanisms of action and synergy with drugs against fungal pathogens. *Front. Microbiol.***8**, 1–10 (2017).
57. Kobayashi, T. *et al.* Synergistic antifungal effect of lactoferrin with azole antifungals against *Candida albicans* and a proposal for a new treatment method for invasive candidiasis. *Jpn. J. Infect. Dis.***64**, 292–296 (2011).
58. Lupetti, A. *et al.* Synergistic activity of the N-terminal peptide of human lactoferrin and fluconazole against *Candida* species. *Antimicrob. Agents Chemother.***47**, 262–267 (2003).
59. Bondaryk, M., Staniszevska, M., Zielińska, P. & Urbańczyk-Lipkowska, Z. *Natural antimicrobial peptides as inspiration for design of a new generation antifungal compounds*. *Journal of Fungi* vol. 3 (2017).
60. Vaitkienė, S. *et al.* Antifungal activity of styrylpyridinium compounds against *Candida albicans*. *Chem. Biol. Drug Des.***97**, 253–265 (2021).
61. Lum, K. Y. *et al.* Activity of novel synthetic peptides against *Candida albicans*. *Sci. Rep.***5**, (2015).
62. John, C. N., Abrantes, P. M. D. S., Prusty, B. K., Ablashi, D. V. & Africa, C. W. J. K21 compound, a potent antifungal agent: Implications for the treatment of fluconazole-resistant HIV-associated *Candida* species. *Front. Microbiol.***10**, (2019).
63. Tits, J. *et al.* Combination of miconazole and domiphen bromide is fungicidal against biofilms of resistant *Candida* spp. *Antimicrob. Agents Chemother.***64**, (2020).
64. Wani, F. A. *et al.* Synthesis of Novel Benzimidazolium Gemini Surfactants and Evaluation of Their Anti-*Candida* Activity. *ACS Omega***4**, 11871–11879 (2019).

65. Pfaller, M. A. *et al.* *Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard – second edition serving the world 's medical science community through voluntary consensus.* vol. 22 (2002).
66. Krom, B. P. *et al.* *Conditions for Optimal Candida Biofilm Development in Microtiter Plates [in:] Candida albicans methods and protocols.* (Humana Press, a part of Springer Science+Business Media, LLC, 2009).
67. Nilius, A. M. *Antimicrobial pharmacodynamics in theory and clinical practice. Shock* vol. 17 (2002).

Figures




Figure 1

MIC value distribution of the tested compounds: (A) – fluconazole, (B) - lipopeptides L1 and C1, (C) - lipopeptides L2 and C2.




Figure 2

MBEC value distribution of the tested compounds: (A) - fluconazole, (B) - lipopeptides L1 and C1, (C) - lipopeptides L2 and C2.




Figure 3

Interpretation of the determined FIC indices (SYN - synergy, ADD - addition, IND - indifference, ANT - antagonism) : (A) L1; (B) C1; (C) L2; (D) C2; and with differentiation between *C. albicans* and NCAC isolates: (E) L1; (F) C1; (G) L2; (H) C2.




Figure 4

Distribution of FIC indices for combination fluconazole-L1; (A) total – 64 strains; (B) *C. albicans* – 53 strains; (C) NCAC – 11 strains.




Figure 5

Distribution of FIC indices for the combination fluconazole-C2; (A) total – 64 strains; (B) *C. albicans* – 53 strains; (C) NCAC – 11 strains.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementarydataCzechowicz.docx](#)
- [formula.docx](#)